Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 12  |  Issue : 5  |  Page : 109--115

A comparison of drug resistances of targeted drugs for advanced renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical trials


Ming Guo1, Yunsong Cao2, Jingzhe Yang3, Jingfeng Zhang2 
1 Department of Hematology, 2nd Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078, China
2 Department of Nephrology, 2nd Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078, China
3 Department of Urology and Andragogy, 2nd Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078, China

Correspondence Address:
Jingfeng Zhang
Department of Hematology, Nephrology, 2nd Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100078
China

Purpose: The purpose of this study was to conduct network meta-analysis to assess drug resistances of the Food and Drug Administration-approved drugs for advanced renal cell carcinoma. Materials and Methods: Database searches were conducted to identify randomized controlled trials reporting results for eligible treatments. After searching for PubMed, MEDLINE, EMBASE, and ISI Web of Science, 22 studies (n = 7854 patients) were included for the comparison of drug resistance in the present meta-analysis. Results: For overall present, the mean 6-month progression-free survival rates were 65.4%, 49.3%, 60.6%, 70.3%, 62.6%, 41.6%, 38.2%, 66.1%, 43.1%, and 17.9% for sunitinib, sorafenib, pazopanib, axitinib, bevacizumab plus interferon (IFN)-a, everolimus, temsirolimus, temsirolimus plus bevacizumab, IFN-a, and placebo, respectively. For indirect comparison, two combined therapies (bevacizumab plus IFN-a and temsirolimus plus bevacizumab) and sunitinib were of less ability of drug resistance. The risk ratio of sunitinib therapy was 3.64 (95% confidence interval [CI] [3.12, 4.25]), the risk ratio of temsirolimus plus bevacizumab therapy was 3.68 (95% CI [3.14, 4.33]), and the risk ratio of bevacizumab plus IFN-a therapy was 3.49 (95% CI [2.99, 4.06]). Conclusions: Our results support that combination of targeted therapies might be a novel strategy against advanced renal cell carcinomas.


How to cite this article:
Guo M, Cao Y, Yang J, Zhang J. A comparison of drug resistances of targeted drugs for advanced renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical trials.J Can Res Ther 2016;12:109-115


How to cite this URL:
Guo M, Cao Y, Yang J, Zhang J. A comparison of drug resistances of targeted drugs for advanced renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical trials. J Can Res Ther [serial online] 2016 [cited 2021 Oct 24 ];12:109-115
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=5;spage=109;epage=115;aulast=Guo;type=0